Literature DB >> 17218138

Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus.

Yoko Ushijima1, Chenhong Luo, Fumi Goshima, Yohei Yamauchi, Hiroshi Kimura, Yukihiro Nishiyama.   

Abstract

A spontaneously occurring herpes simplex virus type 1 (HSV-1) mutant, designated HF10, replicates very efficiently and induces extensive cell fusion in most transformed cells as well as Vero cells, but is highly attenuated in mice when inoculated by peripheral routes of infection. Recent studies have shown that HF10 is a promising agent for use in oncolytic virotherapy. In this study, we sequenced the genome of HF10 and compared it with that of HSV-1 strain 17, a reference strain with the syn+ phenotype. The sequencing covered whole regions corresponding to all open reading frames of strain 17, and the overall putative amino acid identity between HF10 and strain 17 was 99.1% except for proteins encoded by three genes with frame-shift mutations. HF10 had a number of deletions and insertions in the genome, resulting in the lack of the functional expression of UL43, UL49.5, UL55, UL56 and latency-associated transcripts. Additionally, HF10 had amino acid changes in genes involved in the regulation of syncytium formation, including UL1, UL20, UL22, UL24, UL27 and UL53. The proteins encoded by UL1, UL2, UL11, UL44, US1, US7, US8.5, US10 and US12 exhibited a relatively high divergence. These data provide the genetic background of HF10 and insight into the molecular mechanism of HSV-1 replication and pathogenicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17218138     DOI: 10.1016/j.micinf.2006.10.019

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  33 in total

1.  Herpesvirus systematics.

Authors:  Andrew J Davison
Journal:  Vet Microbiol       Date:  2010-02-11       Impact factor: 3.293

2.  Oncolytic virotherapy for ovarian cancer.

Authors:  Shoudong Li; Jessica Tong; Masmudur M Rahman; Trevor G Shepherd; Grant McFadden
Journal:  Oncolytic Virother       Date:  2012-08

3.  Sequence variability in clinical and laboratory isolates of herpes simplex virus 1 reveals new mutations.

Authors:  Moriah L Szpara; Lance Parsons; L W Enquist
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

4.  Recent advances of oncolytic virus in cancer therapy.

Authors:  Moumita Mondal; Jingao Guo; Ping He; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-02-20       Impact factor: 3.452

Review 5.  Oncolytic HSV-1 virotherapy: clinical experience and opportunities for progress.

Authors:  Balveen Kaur; E Antonio Chiocca; Timothy P Cripe
Journal:  Curr Pharm Biotechnol       Date:  2012-07       Impact factor: 2.837

6.  The efficacy of combination therapy with oncolytic herpes simplex virus HF10 and dacarbazine in a mouse melanoma model.

Authors:  Rui Tanaka; Fumi Goshima; Shinichi Esaki; Yoshitaka Sato; Takayuki Murata; Yukihiro Nishiyama; Daisuke Watanabe; Hiroshi Kimura
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

Review 7.  The Role of Oncolytic Viruses in the Treatment of Melanoma.

Authors:  Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Oncol Rep       Date:  2018-08-25       Impact factor: 5.075

8.  Herpes simplex virus UL56 interacts with and regulates the Nedd4-family ubiquitin ligase Itch.

Authors:  Yoko Ushijima; Chenhong Luo; Maki Kamakura; Fumi Goshima; Hiroshi Kimura; Yukihiro Nishiyama
Journal:  Virol J       Date:  2010-08-03       Impact factor: 4.099

9.  Novel mutations in gB and gH circumvent the requirement for known gD Receptors in herpes simplex virus 1 entry and cell-to-cell spread.

Authors:  Hiroaki Uchida; Janet Chan; Indira Shrivastava; Bonnie Reinhart; Paola Grandi; Joseph C Glorioso; Justus B Cohen
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  HSV, axonal transport and Alzheimer's disease: in vitro and in vivo evidence for causal relationships.

Authors:  Elaine L Bearer
Journal:  Future Virol       Date:  2012-09       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.